Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Opening Session Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Amit Sanyal, MD: A Clinician’s Perspective

Aug

Today In Oncology

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Opening Session Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Amit Sanyal, MD: A Clinician’s Perspective

When Diagnosis Waits: Lung Cancer, PET Access, and Global Oncology

Phase I Trial Evaluates Allogeneic CD70-Targeted CAR T-Cell Therapy in Advanced Renal Cell Carcinoma

Combination Regimen Prolongs PFS in dMMR-MSI-H Metastatic Colorectal Cancer

CKM Syndrome Associated With Increased, Stage-Specific Cancer Risk, Study Finds

Population-Based MGUS Screening Enables Earlier Detection of Multiple Myeloma Without Increasing Psychological Distress